ProMIS Neurosciences (PMN) Earnings Date & Reports

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimerâ€™s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PMN is expected to report earnings to fall 25.43% to -15 cents per share on August 18

ProMIS Neurosciences PMN Stock Earnings Reports

Q2'25

Est.

$-0.16

Q1'25

Missed

by $0.06

Q4'24

Beat

by $0.28

Q3'24

Beat

by $0.38

Q2'24

Beat

by $0.01

The last earnings report on May 13 showed earnings per share of -20 cents, missing the estimate of -15 cents. With 25.79K shares outstanding, the current market capitalization sits at 17.00M.

View a ticker or compare two or three

Compare

PMN